Shots:

• The RELIEF study evaluating the efficacy & safety of VYEPTI (100mg- 30-minute IV infusion) vs PBO in a ratio (1:1) in 480 patients with migraine- administered within 1-6 hrs of migraine attack
• The study met its co-primary EPs i.e.- median time to headache pain freedom (4 hrs vs 9 hrs) & median time to absence of MBS (2 hrs vs 3 hrs) & 2EPs @ 2hrs post-infusion- demonstrates headache pain freedom (23.5% & 12%)- absence of MBS (55.5% & 35.8%)- patients required rescue medications (31.5% vs 59.9%) @ 24 hrs treatment
• The exploratory EPs of time to next migraine (10 vs 5 days) and was well-tolerated while safety & tolerability also assessed & compare to safety data from 2 P-III studies- PROMISE 1 & PROMISE 2

  | Ref: Business Wire | Image: Berlingske